Cannabis Law Report

MAY 1, 2023

million to support the development of its MDMA-assisted therapy program in a tranche led by Sixty Two Capital and Taylor Collison. Biotech Emyria (ASX: EMD) has raised $2.5

Therapy 52

Therapy Programs 52

Canna Law Blog

NOVEMBER 27, 2021

is expanding rapidly as numerous neuropharmaceutical companies look to be among the first-to-market potentially revolutionary therapies. In September, the Nikean Foundation announced a $5 million gift to create a psychedelic therapy research center at the University of Toronto. The post DMT Therapy: Coming to a Clinic Near You?

Therapy 88

Therapy Clinical Trials DEA Microdosing 88

MMJ Recs

JANUARY 24, 2024

The landscape of healthcare and medicinal practices has undergone a transformative shift with the advent of medical marijuana programs across the United States. Today we’ll take a closer look at the Michigan Medical Marijuana Program, giving Michigan citizens all the info they need about accessing MMJ in the state.

Programs 52

Programs Marijuana Access Chronic Pain 52

Cannabis Law Report

JUNE 16, 2021

This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada. We are excited to explore the potential of emergent psychedelic therapies. ABOUT SANTÉ CANNABIS. Santé Cannabis is at the forefront of safe and supported patient access to complementary medicines.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

OCTOBER 14, 2021

International Summit on Psychedelic Therapies for Mental Illness. Why do we need psychedelic-assisted therapies? A range of videos and programs for our delegates viewing. Living until you die – the promise of psilocybin-assisted therapy with terminally ill patients. This program is subject to change. Session 1.

Therapy 105

Therapy Medicine Treatment Programs 105

MassRoots

AUGUST 3, 2020

New laws expanding the medical marijuana program in Louisiana went into effect on August 1. The state’s medical marijuana program has been criticized for being too limited and too restrictive since the program was established in 2016, but the three laws that went into effect on Saturday aim to improve the situation.

Programs 124

Programs Banking Marijuana Conditions 124

Cannabis Law Report

MARCH 27, 2023

. (“ATMA”), Canada’s leading psychedelic-assisted therapy training provider, begins its first psychedelic training program highly focused on psilocybin and MDMA, designed for physicians, psychiatrists and prescribers starting April 14, 2023.

Programs 52

Programs Therapy 52

Cannabis Law Report

MAY 19, 2022

5 restored its “Special Access Program” — abolished under former prime minister Stephen Harper in 2013 — allowing health-care experts to request access to restricted drugs that have not yet been authorized for sale in the country. “The therapy part has a capital T in this whole process,” Hartle said.

Therapy 52

Therapy Patients Treatment Clinical Trials 52

Cannabis Law Report

JULY 13, 2022

Physicians and researchers are urging New Mexico legislators to allow the use of psychedelic mushrooms in mental health therapy aimed at overcoming depression, anxiety, psychological trauma and alcoholism. He warned legislators that public interest is spawning illicit, underground experimentation without safeguards. “I

Therapy 52

Therapy Legislation Access Decriminalization 52

Veriheal

APRIL 3, 2024

Naropa University in Boulder, Colorado, has created an exciting new initiative for students: a minor in psychedelic studies, designed to train those who want to practice psychedelic-assisted therapy and other related careers. The minor is a bachelor of arts program encompassing 12 total credits. Joseph Harrison, M.S.,

Therapy 67

Therapy Education Programs Medicine 67

Cannabis Law Report

FEBRUARY 24, 2022

Canada recently amended its Controlled Drugs and Substances Act (CDSA) to allow for psilocybin and MDMA therapy in limited circumstances. Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions. Conclusion.

Therapy 52

Therapy Access Clinical Trials Treatment 52

Cannabis Law Report

JANUARY 25, 2023

Last week, La Shawn K. Ford, a Democratic member of the Illinois House of Representatives, introduced the Compassionate Use and Research of Entheogens Act, or CURE Act, as the very first bill during the opening session of Illinois 103rd General Assembly.

Therapy 52

Therapy Programs Legislation Law 52

Canna Law Blog

NOVEMBER 10, 2020

I was talking to another lawyer about last week’s vote by Oregonians to legalize psilocybin therapy here in the state. Or because Right to Try is similar to FDA’s existing expanded access program (often referred to as the “compassionate use” program). Or, it could be because FDA is sort of a drag about everything.

Therapy 79

Therapy Clinical Trials Decriminalization Patients 79

Veriheal

JUNE 29, 2021

In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine. The FDA refers to this program as the expanded access program on their website. Cannabinoid Therapies for Cancer Patients.

Therapy 55

Therapy DEA Patients Clinical Trials 55

Cannabis Law Report

OCTOBER 20, 2021

International Summit on Psychedelic Therapies for Mental Illness 17-20 November 2021. The event will also feature a two-day pre-Summit Introductory Workshop Program (17-18 November) led by Nigel Denning, Dr Tra-ill Dowie with world-leading therapist trainer Dr Bill Richards (USA) from Johns Hopkins University.

Therapy 52

Therapy Medicine Topical Events 52

Cannabis Law Report

APRIL 2, 2022

Founded in 2019, Roots to Thrive is Canada’s first and only multidisciplinary, non-profit healthcare practice to legally offer evidence-informed, multi-week group therapy programs that include psilocybin-assisted and ketamine-assisted group therapy sessions.

Therapy 52

Therapy Research and Development Programs Legalization 52

Cannabis Law Report

JULY 13, 2022

Optimi will supply Bloom with sufficient biomass of natural psilocybin to begin conducting its previously announced clinical trial in partnership with the IMPACT Clinical Trial Accelerator Program housed within Alberta’s Life Sciences Innovation Hub at the University of Calgary.

Therapy 52

Therapy Clinical Trials Microdosing Research and Development 52

Cannabis Law Report

MARCH 9, 2023

OPB reports An executive for Synthesis Institute informed students Monday that the business was bankrupt and would end its efforts to deliver therapy under Measure 109. million tractsouth of Ashland in June 2021, the company hailed it as the future of psychedelic-assisted therapy in Oregon. […]

Programs 52

Programs Therapy Business 52

Veriheal

FEBRUARY 14, 2024

Under the new measure, the Department of Human Services (DHS) will be able to offer licenses to psilocybin therapy centers with trained therapists and psychedelic facilitators. The goal is to ensure that psychedelic therapy remains safe, accessible, and affordable to those 21 and older.

Therapy 62

Therapy Legalization Research and Development Treatment 62

Cannabis Law Report

MAY 4, 2022

Under both the budget bill and HB 5396 , psychedelic treatment centers would be established in the state where people could receive psilocybin-assisted or MDMA-assisted therapy as part of an expanded access program for investigational new drugs through the federal Food and Drug Administration (FDA).

Treatment 52

Treatment Programs Therapy Access 52

Cannabis Law Report

OCTOBER 22, 2021

(TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce that following discussions with the U.K. Small Pharma initiated a clinical program into DMT-assisted therapy in February 2021. For further information contact: .

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

FEBRUARY 9, 2022

This is a breakthrough therapy and it shows promise, but the science is not there yet.”. A Maine therapist with two patients benefiting from psychedelic drug-assisted therapy to treat PTSD and depression also expressed disappointment. A 43-year-old Portland man said psilocybin therapy helped him forgive himself and others.

Therapy 52

Therapy Treatment Decriminalization Patients 52

Veriheal

JANUARY 18, 2024

Cannabis nurses are crucial in bridging the gap between traditional healthcare and emerging cannabis therapies. These nurses also offer valuable insights on integrating cannabis therapies into various healthcare settings, including dispensaries, primary care clinics, and specialized pain management centers. So what does it all mean?

Education 113

Education Therapy Patients Research and Development 113

MMJ Recs

MAY 9, 2024

There are multiple US states with an established state-approved medical marijuana program as well as states permitting the use of cannabinol (CBD) oil – a non-psychoactive component of cannabis – for medical purposes exclusively.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Veriheal

JULY 2, 2020

Louisiana has had a medical cannabis program for many years. In late May, Louisiana lawmakers discussed a bill that would significantly expand the state’s medical cannabis program and offer access to thousands of more patients in the state that may benefit from cannabinoid therapies. The Bill as Passed.

Banking 52

Banking Programs Therapy Conditions 52

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The Innovative Licensing and Access Pathway (ILAP) Innovation Passport has ben granted to MDMA as an adjunct to therapy for posttraumatic stress disorder (PTSD) in the United Kingdom (UK).

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

NORML

MAY 19, 2020

House lawmakers have overwhelmingly approved two bills to amend the state’s medical marijuana program in a manner that significantly expands patients’ access to cannabis products. The state’s medical cannabis program became operational last August.

Access 257

Access Therapy Patients Conditions 257

Cannabis Law Report

MARCH 15, 2021

David Bronner calls out the never ending creep of Compass or as he puts it…… Their monopolistic and shady… Read More.

Therapy 64

Therapy Programs 64

The Joint Blog

JUNE 15, 2020

According to NORML participants in the study were enrolled in Israel’s federal marijuana access program and were able to choose from four select strains of cannabis. Patients were most likely to eliminate their use of opioids, anxiolytics, and anti-depressants after initiating cannabis therapy.”

Therapy 59

Therapy Environment Pharmaceutical Consumption 59

NORML

JUNE 15, 2020

Late last week, the Governor signed House Bill 819, which expands the discretion of physicians so that they can recommend cannabis therapy for “any condition” that he or she “considers debilitating to an individual patient and is qualified through his [or her] medical education and training to treat.”

Access 323

Access Patients Law Therapy 323

Cannabis Law Report

DECEMBER 5, 2021

Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once certain financial milestones are met.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Veriheal

JULY 6, 2021

Wait, Tennessee has a medical cannabis program? The Evolution of Tennessee’s Medical Cannabis Program. In late May of 2021, the Governor of Tennessee Bill Lee signed off on legislation that will expand the limited CBD program in Tennessee and create a new commission to study broader medical cannabis legalization in the state.

Programs 52

Programs Oil Epilepsy THC 52

Cannabis Law Report

JUNE 16, 2019

On May 13th New Jersey’s Department of Health (“DOH”) amended it Medicinal Marijuana Program Rules, N.J.A.C. Phil Murphy’s Executive Order #6 tasking the DOH with reviewing all Medicinal Marijuana Program (“Program”) aspects to expand access and eliminate bureaucratic barriers. 24:6I-1, Et.

Programs 77

Programs Chronic Pain Marijuana Conditions 77

Cannabis Law Report

MAY 6, 2021

EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS).… … Read More.

Clinical Trials 59

Clinical Trials Therapy Programs Medicine 59

Cannabis Law Report

MAY 17, 2023

Marijuana Moment reports A North Carolina House committee has approved a bill to create a $5 million grant program to support research into the therapeutic potential of psilocybin and MDMA and to create a Breakthrough Therapies Research Advisory Board to oversee the effort. Edward Goodwin (R) and other […]

Therapy 98

Therapy Legislation Programs Marijuana 98

SpeedWeed

JUNE 1, 2021

Andrew Yang announced on May 27 that if elected to the office of mayor of New York City, he would personally push to invest in veterans and allow the use of psychedelic therapies for those suffering from disorders such as depression, suicide, homelessness and post-traumatic stress disorder (PTSD). methamphetamine (MDMA).

Therapy 40

Therapy Treatment Pharmaceutical Conditions 40

Veriheal

JULY 18, 2023

The Grant Program Details The heart of this landmark legislation lies in the development of a robust grant program. Notably, the grant program will target three prevalent and often debilitating conditions in military personnel: PTSD, traumatic brain injury (TBI) , and chronic traumatic encephalopathy (CTE).

Treatment 98

Treatment Clinical Trials Research and Development Legislation 98